Eli Lilly will pay $3.25bn up front to acquire Kelonia Therapeutics, a developer of in‑vivo CAR‑T therapies, with contingent clinical, regulatory and commercial payments that could lift the total to $7bn. The companies said the transaction is expected to close in the second half of 2026.

Deal terms and timing Eli Lilly has agreed to acquire Kelonia Therapeutics in a deal valued at as much as $7 billion, the companies said on Monday. Lilly will make an immediate cash payment of $3.25 billion, with the remainder tied to clinical, regulatory and commercial milestones that could lift the total to $7 billion if all conditions are met. The transaction is set to close in the second half of 2026. The structure — a large upfront sum followed by contingent payments — is familiar in big pharma deals. It limits Lilly's near-term cash outlay while giving Kelonia shareholders upside if the candidate therapies perform well in trials and win approvals. Jacob Van Naarden, president of Lilly Oncology and head of corporate business development, described the approach to treatment as "an intravenously delivered therapy, one time." He told reporters the therapy targets patients' T‑cells inside the body and needs no preconditioning before dosing. How in vivo CAR‑T differs from current cell therapies Kelonia's platform aims to reprogram a patient's T‑cells inside the body — a technique known as in vivo CAR‑T. Traditional CAR‑T therapies are manufactured outside the body. Clinicians harvest a patient's blood cells, send them to a factory for genetic engineering, then return the altered cells weeks later. That ex vivo process has been effective for certain blood cancers, but it's complex and concentrated in specialist centres. In vivo CAR‑T seeks to do that engineering inside the patient after a single intravenous infusion. That could shorten treatment timelines and open access beyond academic hospitals that run ex vivo programmes. Van Naarden said Lilly sees convenience and broader reach as major advantages of an in vivo approach. Market context: who's already selling and who's buying The CAR‑T market has already produced blockbuster revenues, and competing deals have pushed valuations higher: major biotechs have paid billions for partners with rival candidates, underscoring how large firms often buy capabilities rather than starting programmes from scratch. Lilly's CEO and board have been explicit about using earnings from their successful GLP‑1 drugs to broaden the firm's portfolio. Recent acquisitions include developers focused on sleep disorders and on cutting‑edge cell therapies. The company has shifted from buying small experimental assets to paying higher prices for later‑stage platforms, and the Kelonia deal continues that pattern. Why Lilly is making the move now Lilly's oncology unit wants to be a major player in haematology, the company says. The in vivo approach could let Lilly offer a one‑time infusion that treats blood cancers without the weeks‑long manufacturing step and chemotherapy preconditioning that ex vivo CAR‑T requires. That would make cell therapy more like a conventional drug from a hospital logistics standpoint. Van Naarden said Lilly plans to deploy Kelonia's technology not only in multiple myeloma but also across other blood cancers and potentially in solid tumours. Commercial upside and financial framing For Lilly, the transaction is a bet on both science and reach. If the in vivo approach proves safe and effective in larger trials, it could unlock significant commercial potential if approved and broadly adopted.

Related Articles

Lilly plans to deploy Kelonia's platform in multiple myeloma, other blood cancers and potentially solid tumours, and the companies expect to close the deal in the second half of 2026.

This article was created with AI assistance.